Abstract：
The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These malignancies tend to affect young patients and their prognosis is poor given the lack of effective treatments. Characteristically, these tumors are highly infiltrated by TILs, suggesting that some lymphocytes are recognizing tumor antigens. The use of those TILs as a therapeutic strategy is a promising approach worth exploring. Here, we report the clinical protocol of the TILTS study, a Phase II clinical trial assessing personalized adoptive cell therapy with TILs in patients affected by these tumor types.Clinical Trial Registration: 2023-504632-17-00 (www.clinicaltrialsregister.eu) (ClinicalTrials.gov).
[Box: see text].
[Box: see text].
摘要：
SWI/SNF复合物是由几种蛋白质如SMARCA4或SMARCB1包含的染色质重塑复合物。其成分的突变可导致侵袭性横纹肌样瘤的发展，如上皮样肉瘤，恶性横纹肌样瘤或卵巢高钙血症型小细胞癌，在其他人中。这些恶性肿瘤往往会影响年轻患者，并且由于缺乏有效的治疗方法，其预后较差。典型地，这些肿瘤被TIL高度浸润，表明一些淋巴细胞识别肿瘤抗原。使用这些TIL作为治疗策略是值得探索的有希望的方法。这里,我们报告了TILTS研究的临床方案，一项II期临床试验，评估在受这些肿瘤类型影响的患者中使用TIL进行个性化过继细胞治疗。临床试验注册：2023-504632-17-00（www。临床试验登记。欧盟)(ClinicalTrials.gov)。
[方框：见正文]。
[方框：见正文]。
